Le Lézard
Classified in: Health
Subject: SVY

Global Regenerative Medicines Market Report 2020-2030: 230+ Products and Services, 50 Brands, 350 Pipeline Products, 50+ Companies

DUBLIN, April 21, 2021 /PRNewswire/ -- The "Global Regenerative Medicines Market 2020-2030: Focus on Products, Applications, 17 Countries' Data and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global regenerative medicines market is projected to reach $87.03 billion by 2030. The study also highlights that the market is set to witness a CAGR of 13.99% from 2020 and 2030.

The market is driven by certain factors, including increasing consolidation among healthcare juggernauts, rising number of clinical trials for regenerative therapies, a favorable regulatory environment to accelerate approvals and market entry, and rising awareness for stem cell therapeutics, that are fueling the growth of the global regenerative medicines market.

Regenerative medicine is challenging the current healthcare practices by targeting the treatment of the root causes of disease and disorders, transforming it into an incredibly exciting space. However, these advancements have not come without significant challenges and uncertainties, which will also further need to be overcome to realize the full potential of regenerative medicine.

This comprehensive study of the regenerative medicines market extensively covers the following:

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 550+ products, services, and pipeline potential.

The study indicates increasing consolidation among healthcare juggernauts, a rising number of clinical trials for regenerative therapies, a favorable regulatory environment to accelerate approvals and market entry, and an increasing awareness for stem cell therapeutics are fueling the growth of the global regenerative medicines market.

The market intelligence additionally throws a spotlight on the opportunities existing in the market, such as drug approvals and a strong pipeline of cell and gene therapies, multiple investments into building cGMP facilities, and innovations in regenerative medicine, among others.

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include types of products and services, applications, and regions. The products and services segment and the region segments have been further sub-segmented to offer an in-depth analysis of the global regenerative medicines market.

The product and ecosystem analysis of the global market includes data analysis on the type of offerings available in the market. Pertaining to the market segmentation, the product segment is segmented broadly into tissue engineering products, stem cell products and services, and cell and gene therapy products. The tissue engineering segment has been further segmented into allogenic tissue, autologous tissue, xenogeneic tissue, synthetic tissue, and other tissue products. The stem cell products and services segment has been further segmented into stem cell services and stem cell therapeutics.

Further, cell and gene therapy has been segmented into cell therapy and gene therapy. The cell therapy segment has also been segmented into CAR-T therapies and other cell therapies.

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include AbbVie, Inc., Baxter International Inc., Becton, Dickinson and Company, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Mesoblast Ltd., Novartis International A.G., NuVasive, Inc., Organogenesis Holdings, Inc., Smith & Nephew plc, Stryker Corporation, Vericel Corporation, and Zimmer Biomet Holdings, Inc.

The study also offers strategic recommendations that can help organizations in tracking various products and trends that are changing the dynamics of the market. The recommendations by the analyst also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?

How can market intelligence on regenerative medicines add value to an organization's decision-making process?

Market Dynamics

Market Drivers

Market Restraints


Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/sj39ob

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

These press releases may also interest you

at 21:55
Applied DNA Sciences, Inc. (Applied DNA or the "Company"), today clarifies the scope of its newly authorized asymptomatic serial screening indication for its Linea COVID-19 Assay Kit (the "Assay Kit") and certain information contained in its...

at 21:15
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its financial results and operational highlights for the first quarter...

at 21:08
Americans spend nearly twice as much for prescription medication compared to what residents of other countries pay. The comparison is with modern countries with good healthcare provisioning systems too, so the question becomes why are drugs so...

at 21:05
As the world joins together to fight the ongoing battle against the COVID-19 pandemic, Terumo Corporation (TSE: 4543) has announced that the Terumo Group companies will collectively donate USD 1 million in cash to support the COVID-19 Solidarity...

at 21:00
The allergy immunotherapies market is poised to grow by USD 713.56 million during 2021-2025, progressing at a CAGR of almost 8% during the forecast period. Here is an Exclusive report talking about Market scenarios, Estimates, the impact of...

at 20:40
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology,...

News published on 21 april 2021 at 07:45 and distributed by: